• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

“魔法”甲基的作用:2'-脱氧-2'-α-F-2'-β--甲基嘧啶核苷酸通过与 5'-磷酸类似物的协同作用和减轻脱靶效应来调节 RNA 干扰活性。

Role of a "Magic" Methyl: 2'-Deoxy-2'-α-F-2'-β--methyl Pyrimidine Nucleotides Modulate RNA Interference Activity through Synergy with 5'-Phosphate Mimics and Mitigation of Off-Target Effects.

机构信息

Alnylam Pharmaceuticals, 675 West Kendall, Cambridge, Massachusetts 02142, United States.

Department of Biochemistry, School of Medicine, Vanderbilt University, Nashville, Tennessee 37232, United States.

出版信息

J Am Chem Soc. 2022 Aug 17;144(32):14517-14534. doi: 10.1021/jacs.2c01679. Epub 2022 Aug 3.

DOI:10.1021/jacs.2c01679
PMID:35921401
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9389587/
Abstract

Although 2'-deoxy-2'-α-F-2'-β--methyl (2'-F/Me) uridine nucleoside derivatives are a successful class of antiviral drugs, this modification had not been studied in oligonucleotides. Herein, we demonstrate the facile synthesis of 2'-F/Me-modified pyrimidine phosphoramidites and their subsequent incorporation into oligonucleotides. Despite the C3'- preorganization of the parent nucleoside, a single incorporation into RNA or DNA resulted in significant thermal destabilization of a duplex due to unfavorable enthalpy, likely resulting from steric effects. When located at the terminus of an oligonucleotide, the 2'-F/Me modification imparted more resistance to degradation than the corresponding 2'-fluoro nucleotides. Small interfering RNAs (siRNAs) modified at certain positions with 2'-F/Me had similar or better silencing activity than the parent siRNAs when delivered via a lipid nanoparticle formulation or as a triantennary -acetylgalactosamine conjugate in cells and in mice. Modification in the seed region of the antisense strand at position 6 or 7 resulted in an activity equivalent to the parent in mice. Additionally, placement of the antisense strand at position 7 mitigated seed-based off-target effects in cell-based assays. When the 2'-F/Me modification was combined with 5'-vinyl phosphonate, both and isomers had silencing activity comparable to the parent. In combination with other 2'-modifications such as 2'--methyl, the isomer is detrimental to silencing activity. Presumably, the equivalence of 5'-vinyl phosphonate isomers in the context of 2'-F/Me is driven by the steric and conformational features of the -methyl-containing sugar ring. These data indicate that 2'-F/Me nucleotides are promising tools for nucleic acid-based therapeutic applications to increase potency, duration, and safety.

摘要

尽管 2'-脱氧-2'-α-F-2'-β--甲基(2'-F/Me)尿嘧啶核苷衍生物是一类成功的抗病毒药物,但这种修饰在寡核苷酸中尚未得到研究。在此,我们展示了嘧啶磷酰胺类似物的简便合成及其随后在寡核苷酸中的掺入。尽管母体核苷的 C3'-预组织,但由于不利的焓,单个掺入 RNA 或 DNA 会导致双链体显著热不稳定性,可能是由于空间位阻效应所致。当位于寡核苷酸的末端时,2'-F/Me 修饰赋予比相应的 2'-氟核苷酸更高的抗降解能力。在某些位置用 2'-F/Me 修饰的小干扰 RNA (siRNA) 经脂质纳米颗粒制剂或三触角乙酰半乳糖胺缀合物递送至细胞和小鼠中时,其沉默活性与母体 siRNA 相似或更好。反义链在位置 6 或 7 的种子区域进行修饰会导致在小鼠中的活性与母体相当。此外,反义链在位置 7 的放置减轻了基于种子的脱靶效应在细胞测定中。当 2'-F/Me 修饰与 5'-乙烯基膦酸酯结合时,和 异构体都具有与母体相当的沉默活性。与其他 2'-修饰(如 2'---甲基)结合时,异构体对沉默活性有害。据推测,在 2'-F/Me 背景下 5'-乙烯基膦酸酯异构体的等效性是由含--甲基的糖环的空间和构象特征驱动的。这些数据表明,2'-F/Me 核苷酸是用于基于核酸的治疗应用的有前途的工具,可以提高效力、持续时间和安全性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/3c40f41e9f4f/ja2c01679_0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/bde98b9e8295/ja2c01679_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/f79a5606c0ba/ja2c01679_0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/8ca3ef94fe74/ja2c01679_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/7d9992de2f4e/ja2c01679_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/375f9cca93a6/ja2c01679_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/1c10156fcfd5/ja2c01679_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/0073c8578fe2/ja2c01679_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/29ee77bc1a0c/ja2c01679_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/6555dcc1efc5/ja2c01679_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/b246036b4e91/ja2c01679_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/8c7549fc1271/ja2c01679_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/3c40f41e9f4f/ja2c01679_0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/bde98b9e8295/ja2c01679_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/f79a5606c0ba/ja2c01679_0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/8ca3ef94fe74/ja2c01679_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/7d9992de2f4e/ja2c01679_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/375f9cca93a6/ja2c01679_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/1c10156fcfd5/ja2c01679_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/0073c8578fe2/ja2c01679_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/29ee77bc1a0c/ja2c01679_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/6555dcc1efc5/ja2c01679_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/b246036b4e91/ja2c01679_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/8c7549fc1271/ja2c01679_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6077/9389587/3c40f41e9f4f/ja2c01679_0012.jpg

相似文献

1
Role of a "Magic" Methyl: 2'-Deoxy-2'-α-F-2'-β--methyl Pyrimidine Nucleotides Modulate RNA Interference Activity through Synergy with 5'-Phosphate Mimics and Mitigation of Off-Target Effects.“魔法”甲基的作用:2'-脱氧-2'-α-F-2'-β--甲基嘧啶核苷酸通过与 5'-磷酸类似物的协同作用和减轻脱靶效应来调节 RNA 干扰活性。
J Am Chem Soc. 2022 Aug 17;144(32):14517-14534. doi: 10.1021/jacs.2c01679. Epub 2022 Aug 3.
2
Re-Engineering RNA Molecules into Therapeutic Agents.将 RNA 分子重建成治疗剂。
Acc Chem Res. 2019 Apr 16;52(4):1036-1047. doi: 10.1021/acs.accounts.8b00650. Epub 2019 Mar 26.
3
Shorter Is Better: The α-(l)-Threofuranosyl Nucleic Acid Modification Improves Stability, Potency, Safety, and Ago2 Binding and Mitigates Off-Target Effects of Small Interfering RNAs.短链更佳:α-(l)-呋喃核糖核酸修饰可提高稳定性、效力、安全性以及与 Ago2 的结合,并减轻小干扰 RNA 的脱靶效应。
J Am Chem Soc. 2023 Sep 13;145(36):19691-19706. doi: 10.1021/jacs.3c04744. Epub 2023 Aug 28.
4
siRNAs containing 2'-fluorinated Northern-methanocarbacyclic (2'-F-NMC) nucleotides: in vitro and in vivo RNAi activity and inability of mitochondrial polymerases to incorporate 2'-F-NMC NTPs.含 2'-氟代甲基碳桥环核苷酸(2'-F-NMC)的 siRNAs:体外和体内 RNAi 活性以及线粒体聚合酶不能掺入 2'-F-NMC NTP。
Nucleic Acids Res. 2021 Mar 18;49(5):2435-2449. doi: 10.1093/nar/gkab050.
5
Synthesis and antisense properties of fluoro cyclohexenyl nucleic acid (F-CeNA), a nuclease stable mimic of 2'-fluoro RNA.氟环己烯核酸(F-CeNA)的合成及反义性质,一种 2'-氟 RNA 的核酸酶稳定类似物。
J Org Chem. 2012 Jun 1;77(11):5074-85. doi: 10.1021/jo300594b. Epub 2012 May 18.
6
Structural basis for the synergy of 4'- and 2'-modifications on siRNA nuclease resistance, thermal stability and RNAi activity.结构基础:4′-和 2′-修饰在 siRNA 核酸酶抗性、热稳定性和 RNAi 活性方面的协同作用。
Nucleic Acids Res. 2018 Sep 19;46(16):8090-8104. doi: 10.1093/nar/gky703.
7
Acyclic ()-glycol nucleic acid (-GNA) modification of siRNAs improves the safety of RNAi therapeutics while maintaining potency.无环()-乙二醇核酸(-GNA)修饰的 siRNA 提高了 RNAi 治疗的安全性,同时保持了效力。
RNA. 2023 Apr;29(4):402-414. doi: 10.1261/rna.079526.122. Epub 2023 Feb 1.
8
Locked 2'-Deoxy-2',4'-Difluororibo Modified Nucleic Acids: Thermal Stability, Structural Studies, and siRNA Activity.锁定2'-脱氧-2',4'-二氟核糖修饰核酸:热稳定性、结构研究及小干扰RNA活性
ACS Chem Biol. 2015 Sep 18;10(9):2016-23. doi: 10.1021/acschembio.5b00218. Epub 2015 Jun 19.
9
Chimeric siRNAs with chemically modified pentofuranose and hexopyranose nucleotides: altritol-nucleotide (ANA) containing GalNAc-siRNA conjugates: in vitro and in vivo RNAi activity and resistance to 5'-exonuclease.含修饰戊呋喃糖和己吡喃糖核苷酸的嵌合 siRNA:阿糖醇核苷酸(ANA)修饰的 GalNAc-siRNA 缀合物:体外和体内 RNAi 活性以及对 5'-核酸外切酶的抗性。
Nucleic Acids Res. 2020 May 7;48(8):4028-4040. doi: 10.1093/nar/gkaa125.
10
Synthesis, gene silencing, and molecular modeling studies of 4'-C-aminomethyl-2'-O-methyl modified small interfering RNAs.4'-C-氨甲基-2'-O-甲基修饰的小干扰 RNA 的合成、基因沉默及分子建模研究。
J Org Chem. 2012 Apr 6;77(7):3233-45. doi: 10.1021/jo202666m. Epub 2012 Mar 16.

引用本文的文献

1
Single alkyl phosphonate modification of the siRNA backbone in the seed region enhances specificity and therapeutic profile.种子区域中siRNA骨架的单烷基膦酸酯修饰可提高特异性和治疗效果。
Nucleic Acids Res. 2025 Jul 19;53(14). doi: 10.1093/nar/gkaf692.
2
The XNA alphabet.XNA字母表。
Nucleic Acids Res. 2025 Jul 8;53(13). doi: 10.1093/nar/gkaf635.
3
Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines.小核酸疗法全景:作为下一代药物从实验室走向临床

本文引用的文献

1
Delivery of oligonucleotide-based therapeutics: challenges and opportunities.寡核苷酸类治疗药物的递送:挑战与机遇。
EMBO Mol Med. 2021 Apr 9;13(4):e13243. doi: 10.15252/emmm.202013243. Epub 2021 Apr 6.
2
Recent Advances in Oligonucleotide Therapeutics in Oncology.肿瘤学中寡核苷酸治疗的最新进展。
Int J Mol Sci. 2021 Mar 24;22(7):3295. doi: 10.3390/ijms22073295.
3
siRNA Specificity: RNAi Mechanisms and Strategies to Reduce Off-Target Effects.小干扰RNA的特异性:RNA干扰机制及减少脱靶效应的策略。
Signal Transduct Target Ther. 2025 Mar 10;10(1):73. doi: 10.1038/s41392-024-02112-8.
4
Chemical evolution of ASO-like DNAzymes for effective and extended gene silencing in cells.用于细胞中有效且持久基因沉默的类反义寡核苷酸脱氧核酶的化学进化
Nucleic Acids Res. 2025 Feb 27;53(5). doi: 10.1093/nar/gkaf144.
5
Development, opportunities, and challenges of siRNA nucleic acid drugs.小干扰RNA核酸药物的发展、机遇与挑战
Mol Ther Nucleic Acids. 2024 Dec 21;36(1):102437. doi: 10.1016/j.omtn.2024.102437. eCollection 2025 Mar 11.
6
Proximal fleximer analogues of 2'-deoxy-2'-fluoro-2'-methyl purine nucleos(t)ides: Synthesis and preliminary pharmacokinetic and antiviral evaluation.2'-脱氧-2'-氟-2'-甲基嘌呤核苷类似物的近端柔性类似物:合成及初步药代动力学和抗病毒评价。
Bioorg Med Chem. 2024 Oct 1;112:117898. doi: 10.1016/j.bmc.2024.117898. Epub 2024 Aug 24.
7
Atom-Modified gDNA Enhances Cleavage Activity of TtAgo Enabling Ultra-Sensitive Nucleic Acid Testing.原子修饰 gDNA 增强了 TtAgo 的切割活性,使核酸检测达到超高灵敏度。
Adv Sci (Weinh). 2024 Jul;11(28):e2403120. doi: 10.1002/advs.202403120. Epub 2024 May 10.
8
RNAi-based drug design: considerations and future directions.基于 RNAi 的药物设计:考虑因素和未来方向。
Nat Rev Drug Discov. 2024 May;23(5):341-364. doi: 10.1038/s41573-024-00912-9. Epub 2024 Apr 3.
9
Impact of stereopure chimeric backbone chemistries on the potency and durability of gene silencing by RNA interference.立体纯嵌合骨架化学对 RNA 干扰基因沉默效力和持久性的影响。
Nucleic Acids Res. 2023 May 22;51(9):4126-4147. doi: 10.1093/nar/gkad268.
10
Amide Modifications in the Seed Region of the Guide Strand Improve the On-Target Specificity of Short Interfering RNA.引导链种子区的酰胺修饰可提高短干扰 RNA 的靶标特异性。
ACS Chem Biol. 2023 Jan 20;18(1):7-11. doi: 10.1021/acschembio.2c00769. Epub 2022 Dec 29.
Front Plant Sci. 2021 Jan 28;11:526455. doi: 10.3389/fpls.2020.526455. eCollection 2020.
4
siRNAs containing 2'-fluorinated Northern-methanocarbacyclic (2'-F-NMC) nucleotides: in vitro and in vivo RNAi activity and inability of mitochondrial polymerases to incorporate 2'-F-NMC NTPs.含 2'-氟代甲基碳桥环核苷酸(2'-F-NMC)的 siRNAs:体外和体内 RNAi 活性以及线粒体聚合酶不能掺入 2'-F-NMC NTP。
Nucleic Acids Res. 2021 Mar 18;49(5):2435-2449. doi: 10.1093/nar/gkab050.
5
Advances in oligonucleotide drug delivery.寡核苷酸药物递送的进展。
Nat Rev Drug Discov. 2020 Oct;19(10):673-694. doi: 10.1038/s41573-020-0075-7. Epub 2020 Aug 11.
6
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.急性间歇性卟啉症的 RNAi 治疗药物 Givosiran 的 3 期临床试验。
N Engl J Med. 2020 Jun 11;382(24):2289-2301. doi: 10.1056/NEJMoa1913147.
7
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.英克西兰用于治疗杂合子家族性高胆固醇血症。
N Engl J Med. 2020 Apr 16;382(16):1520-1530. doi: 10.1056/NEJMoa1913805. Epub 2020 Mar 18.
8
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.两项降低 LDL 胆固醇的依洛尤单抗 3 期临床试验。
N Engl J Med. 2020 Apr 16;382(16):1507-1519. doi: 10.1056/NEJMoa1912387. Epub 2020 Mar 18.
9
Editorial focus: understanding off-target effects as the key to successful RNAi therapy.社论重点:理解脱靶效应是 RNAi 治疗成功的关键。
Cell Mol Biol Lett. 2019 Dec 9;24:69. doi: 10.1186/s11658-019-0196-3. eCollection 2019.
10
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs.Onpattro的故事以及含核酸类药物的纳米药物的临床转化。
Nat Nanotechnol. 2019 Dec;14(12):1084-1087. doi: 10.1038/s41565-019-0591-y.